| Formulary Chapter 5: Infections - Full Section
|
Notes:
Chapter review date: |
| Useful Links |
 SCAN Guidelines for antibiotic prescribing in the community 2018 |
|
NICE NG182: Insect bites and stings: antimicrobial prescribing (September 2020) |
|
NICE NG153: Impetigo: antimicrobial prescribing (February 2020) |
|
NICE NG152: Leg ulcer infection: antimicrobial prescribing (January 2020) |
|
NICE NG19: Diabetic foot problems: prevention and management (October 2019) |
|
NICE NG138: Pneumonia (community-acquired): antimicrobial prescribing (September 2019) |
|
NICE NG139: Pneumonia (hospital-acquired): antimicrobial prescribing (September 2019) |
|
NICE NG141: Cellulitis and erysipelas: antimicrobial prescribing (September 2019) |
|
NICE NG120: Cough (acute): antimicrobial prescribing (February 2019) |
|
NICE NG114: Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (December 2018) |
|
NICE NG117: Bronchiectasis (acute exacerbation): antimicrobial prescribing (December 2018) |
|
NICE NG112: Urinary tract infection (recurrent): antimicrobial prescribing (October 2018) |
|
NICE NG110: Prostatitis (acute): antimicrobial prescribing (October 2018) |
|
NICE NG111: Pyelonephritis (acute): antimicrobial prescribing (October 2018) |
|
NICE NG109: Urinary tract infection (lower): antimicrobial prescribing (October 2018) |
|
NICE NG95: Lyme Disease (April 2018) |
|
NICE NG91 Otitis media (acute): antimicrobial prescribing (March 2018) |
|
NICE NG84 Sore throat (acute): antimicrobial prescribing (January 2018) |
|
NICE NG79 Sinusitis (acute): antimicrobial prescribing (October 2017) |
|
BHIVA Guidelines |
|
Dental Letter Infective Endocarditis March 2019 |
 Dorset Guidance:Antibiotic Prophylaxis (AP) prior to Dental Treatment to prevent Infective Endocarditis March 2019 |
|
SDCEP Antibiotic Prophylaxis Against Infective Endocarditis |
|
DCHFT: Adult Surgical Antibiotic Treatment Guidelines |
|
DCHFT: IV antibiotic to oral switch guidelines |
|
DCHFT: Medical Directorate Antibiotic Treatment Guidelines |
|
DCHFT: Antibiotic stop / review date and indication policy |
|
DCHFT: Penicillin allergy ’traffic light’ guideline |
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
05.01 |
Antibacterial drugs
(1,0)
|
|
|
Table 1. Summary of antibacterial therapy
(0,0)
|
|
|
Table 2. Summary of antibacterial prophylaxis
(0,0)
|
|
05.01.01 |
Penicillins
(0,0)
|
|
05.01.01.01 |
Benzylpenicillin and phenoxymethylpenicillin
(4,0)
|
|
05.01.01.02 |
Penicillinase-resistant penicillins
(3,0)
|
|
05.01.01.03 |
Broad-spectrum penicillins
(4,2)
|
|
05.01.01.04 |
Antipseudomonal penicillins
(1,1)
|
|
05.01.01.05 |
Mecillinams
(0,0)
|
|
05.01.02 |
Cephalosporins, carbapenems and other beta-lactums
(0,0)
|
|
|
Cephalosporins
(0,0)
|
|
|
Other beta-lactam antibiotics
(0,1)
|
|
05.01.02.01 |
Cephalosporins
(8,5)
|
|
05.01.02.02 |
Carbapenems
(3,0)
|
|
05.01.02.03 |
Other beta-lactums antibiotics
(2,0)
|
|
05.01.03 |
Tetracyclines
(3,3)
|
|
|
Tigecycline
(1,0)
|
|
05.01.04 |
Aminoglycosides
(6,2)
|
|
05.01.05 |
Macrolides
(6,1)
|
|
05.01.06 |
Clindamycin
(2,0)
|
|
05.01.07 |
Some other antibacterials
(3,2)
|
|
|
Chloramphenicol
(1,0)
|
|
|
Fosfomycin
(0,0)
|
|
|
Fusidic acid
(1,0)
|
|
|
Vancomycin and teicoplanin
(3,0)
|
|
|
Daptomycin
(1,0)
|
|
|
Linezolid
(1,0)
|
|
|
Quinupristin and dalfopristin
(0,1)
|
|
|
Polymyxins
(2,0)
|
|
|
Rifaximin
(1,0)
|
|
|
Fidaxomicin
(1,0)
|
|
05.01.08 |
Sulphonamides and trimethoprim
(3,0)
|
|
05.01.09 |
Antituberculosis drugs
(6,9)
|
|
05.01.10 |
Antileprotic drugs
(1,2)
|
|
05.01.11 |
Metronidazole and tinidazole
(2,1)
|
|
05.01.12 |
Quinolones
(7,1)
|
|
05.01.13 |
Urinary-tract infections
(5,0)
|
|
05.02 |
Antifungal drugs
(0,2)
|
|
|
Treatment of fungal infections
(0,0)
|
|
|
Drugs used in fungal infections
(0,2)
|
|
05.02.01 |
Triazole antifungals
(6,0)
|
|
05.02.02 |
Imidazole antifungals
(0,0)
|
|
05.02.03 |
Polyene antifungals
(2,0)
|
|
05.02.04 |
Echinocandin antifungals
(3,0)
|
|
05.02.05 |
Other antifungals
(2,0)
|
|
05.03 |
Antiviral drugs
(1,0)
|
|
05.03.01 |
HIV infection
(1,0)
|
|
|
Nucleoside reverse transcriptase inhibitors
(17,1)
|
|
|
Protease inhibitors
(9,0)
|
|
|
Non-nucleoside reverse transcriptase inhibitors
(4,0)
|
|
|
Other antiretrovirals
(6,1)
|
|
|
Pharmacokinetic enhancers of anti-retrovirals
(0,0)
|
|
|
Combination Products
(0,0)
|
|
05.03.02 |
Herpesvirus infections
(0,1)
|
|
05.03.02.01 |
Herpes simplex and varicella-zoster infection
(4,1)
|
|
05.03.02.02 |
Cytomegalovirus infection
(5,0)
|
|
05.03.03 |
Viral hepatitis
(0,0)
|
|
05.03.03.01 |
Chronic hepatitis B
(3,3)
|
|
05.03.03.02 |
Chronic hepatitis C
(10,4)
|
|
05.03.04 |
Influenza
(3,1)
|
|
05.03.05 |
Respiratory syncytial virus
(2,0)
|
|
05.04 |
Antiprotozoal drugs
(0,0)
|
|
05.04.01 |
Antimalarials
(0,0)
|
|
|
Treatment of malaria
(0,0)
|
|
|
Falciparum malaria (treatment)
(0,0)
|
|
|
Benign malarias (treatment)
(0,0)
|
|
|
Prophylaxis against malaria
(0,0)
|
|
|
Specific recommendations
(0,0)
|
|
|
Artemether with lumefabtrine
(1,0)
|
|
|
Chloroquine
(1,0)
|
|
|
Mefloquine
(1,0)
|
|
|
Primaquine
(1,0)
|
|
|
Proguanil
(1,1)
|
|
|
Pyrimethamine
(1,1)
|
|
|
Quinine
(1,0)
|
|
|
Tetracyclines
(0,0)
|
|
05.04.02 |
Amoebicides
(1,2)
|
|
05.04.03 |
Trichomonacides
(1,0)
|
|
05.04.04 |
Antigiardial drugs
(1,1)
|
|
05.04.05 |
Leishmaniacides
(0,1)
|
|
05.04.06 |
Trypanocides
(0,0)
|
|
05.04.07 |
Drugs for toxoplasmosis
(2,0)
|
|
05.04.08 |
Drugs for pneumocystis pneumonia
(2,0)
|
|
|
Treatment
(0,0)
|
|
|
Prophylaxis
(0,0)
|
|
05.05 |
Anthelmintics
(0,0)
|
|
05.05.01 |
Drugs for threadworms
(1,1)
|
|
05.05.02 |
Ascaricides
(0,0)
|
|
05.05.03 |
Drugs for tapeworm infections
(0,1)
|
|
|
Taenicides
(0,0)
|
|
|
Hydatid disease
(0,0)
|
|
05.05.04 |
Drugs for hookworms
(0,0)
|
|
05.05.05 |
Schistosomicides
(1,0)
|
|
05.05.06 |
Filaricides
(0,0)
|
|
05.05.07 |
Drugs for cutaneous larva migrans
(0,1)
|
|
05.05.08 |
Drugs for strongyloidiasis
(0,0)
|
|
05.06 |
Faecal Microbiota Transplant
(1,0)
|
